Trial intelligence / Profile preview

Fremanezumab versus placebo for preventive treatment of chronic migraine in children and adolescents

MOH_2020-11-12_009498Phase 3Recruiting

Sponsor
Teva Pharmaceutical Industries Ltd.
Start
Nov 2020
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
Countries
1
01

Overview

Phase 3, randomised, double-blind trial in chronic migraine comparing Ajovy with Placebo (2 arms). Started Nov 2020; status: recruiting.

02

Drugs

fremanezumab
03

Conditions

chronic migraine

Beyond the preview

Go deeper on MOH_2020-11-12_009498.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on MOH_2020-11-12_009498.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call